{"id":749,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"essais-cliniques-sur-lara-290-le-cibinetide-la-neuropathie-des-petites-fibres-et-loedeme-diabetique-maculaire","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/","title":{"rendered":"ARA-290\/Cibinetide\u00a0: neuropathie des petites fibres et donn\u00e9es de l'essai DME"},"content":{"rendered":"
Les preuves du cibin\u00e9tide humain comprennent de petites \u00e9tudes exploratoires aupr\u00e8s de populations tr\u00e8s diff\u00e9rentes. Un projet pilote sur la sarco\u00efdose et la neuropathie men\u00e9 sur une personne 22 a signal\u00e9 une diff\u00e9rence de score de sympt\u00f4mes, tandis qu'une \u00e9tude sur l'\u0153d\u00e8me maculaire diab\u00e9tique men\u00e9e aupr\u00e8s d'une personne 9 a manqu\u00e9 ses principales mesures oculaires.<\/p>
Les preuves en un coup d'\u0153il<\/h2>
Le projet pilote randomis\u00e9 sur la sarco\u00efdose a recrut\u00e9 des participants 22\u00a0: 12 a re\u00e7u un placebo ARA-290 et 10.<\/li>
Le changement de SFNSL au cours de la semaine 4 \u00e9tait de \u221211.5 \u00b1 3.04 contre \u22122.9 \u00b1 3.34, tandis que les scores d'intensit\u00e9 de la douleur et de fatigue se sont am\u00e9lior\u00e9s de mani\u00e8re similaire dans les deux groupes.<\/li>
Dans l'\u00e9tude DME, les 9 ont \u00e9t\u00e9 inscrits et les 8 ont \u00e9t\u00e9 compl\u00e9t\u00e9s\u00a0; l\u2019acuit\u00e9 visuelle moyenne, l\u2019\u00e9paisseur de la r\u00e9tine, la sensibilit\u00e9 r\u00e9tinienne et la production de larmes ne se sont pas am\u00e9lior\u00e9es.<\/li><\/ul><\/div><\/div>Illustration originale de recherche \u00e9ditoriale. Il ne s\u2019agit pas d\u2019une figure d\u2019\u00e9tude, d\u2019une image d\u2019un patient, d\u2019une photographie de produit, d\u2019un r\u00e9sultat d\u2019analyse fourni ou d\u2019une repr\u00e9sentation d\u2019un lot du catalogue.<\/figcaption><\/figure>
Dossier d'\u00e9tudes<\/h2>
Le projet pilote sur la neuropathie a signal\u00e9 un changement statistiquement significatif entre les groupes dans la liste de d\u00e9pistage des neuropathies \u00e0 petites fibres. Cependant, le Brief Pain Inventory et les scores de fatigue se sont am\u00e9lior\u00e9s de mani\u00e8re significative mais \u00e9quivalente dans les deux groupes, et l\u2019inventaire de la d\u00e9pression n\u2019a pas chang\u00e9.<\/p>
Conception de la sarco\u00efdose<\/strong>Pilote exploratoire en double aveugle contr\u00f4l\u00e9 par placebo\u00a0; n=22<\/span><\/div>
Changement SFNSL<\/strong>\u221211.5 \u00b1 3.04 versus \u22122.9 \u00b1 3.34 \u00e0 la semaine 4<\/span><\/div>
Conception DME<\/strong>Phase \u00e0 un seul bras 2\u00a0; 9 inscrit, 8 termin\u00e9<\/span><\/div>
Principales mesures DME<\/strong>Aucune am\u00e9lioration moyenne des niveaux BCVA, CRT, de la sensibilit\u00e9 r\u00e9tinienne ou de la production de larmes<\/span><\/div>
Interpr\u00e9tation globale<\/strong>Les signaux g\u00e9n\u00e8rent des hypoth\u00e8ses et non des confirmations<\/span><\/div><\/div><\/div>
R\u00e9sultats en contexte<\/h2>
L\u2019\u00e9tude 2020 sur l\u2019\u0153d\u00e8me diab\u00e9tique-maculaire \u00e9tait encore plus petite. Aux semaines 12, la moyenne de BCVA a chang\u00e9 de \u22122.9 \u00b1 5.0, l'\u00e9paisseur centrale de la r\u00e9tine de 10 \u00b1 94.6 \u00b5m et la sensibilit\u00e9 centrale de la r\u00e9tine de \u22120.53 \u00b1 1.9 dB. Un composite de fonction visuelle rapport\u00e9 par le patient am\u00e9lior\u00e9 de 2.7 \u00b1 3.1, mais la conception \u00e9tait descriptive et non contr\u00f4l\u00e9e.<\/p>
Plusieurs auteurs de l'article DME \u00e9taient des dirigeants, des propri\u00e9taires ou des consultants du d\u00e9veloppeur. Cette divulgation n\u2019invalide pas les r\u00e9sultats, mais elle a sa place \u00e0 c\u00f4t\u00e9 des donn\u00e9es lorsque les lecteurs jugent un petit essai exploratoire.<\/p>
Ce que la preuve ne peut \u00e9tablir<\/h2>
De petits \u00e9chantillons et un suivi court rendent les estimations des effets instables.<\/p>
Diff\u00e9rentes maladies et diff\u00e9rents crit\u00e8res ne peuvent pas \u00eatre combin\u00e9s en une seule et m\u00eame all\u00e9gation g\u00e9n\u00e9rale de \u00ab r\u00e9paration nerveuse \u00bb.<\/p>
Aucune des deux \u00e9tudes n\u2019\u00e9tablit l\u2019\u00e9quivalence avec un mat\u00e9riel de catalogue ou ne soutient une utilisation en dehors de la recherche.<\/p>","protected":false},"excerpt":{"rendered":"
Les preuves du cibin\u00e9tide humain comprennent de petites \u00e9tudes exploratoires aupr\u00e8s de populations tr\u00e8s diff\u00e9rentes. Un projet pilote sur la sarco\u00efdose et la neuropathie men\u00e9 sur une personne 22 a signal\u00e9 une diff\u00e9rence de score de sympt\u00f4mes, tandis qu'une \u00e9tude sur l'\u0153d\u00e8me maculaire diab\u00e9tique men\u00e9e aupr\u00e8s d'une personne 9 a manqu\u00e9 ses principales mesures oculaires.<\/p>","protected":false},"author":1,"featured_media":733,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"315","pim_article_type":"Published evidence review","pim_evidence_level":"Small exploratory human trials; mixed endpoints and no confirmatory efficacy record","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"Randomized ARA-290 sarcoidosis-neuropathy pilot\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23168581\/\",\"note\":\"Primary exploratory trial; PMID 23168581.\"},{\"title\":\"Phase 2 cibinetide diabetic macular edema study\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32674280\/\",\"note\":\"Nine-person study with null principal ocular measures; PMID 32674280.\"},{\"title\":\"PubChem Cibinetide record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Cibinetide\",\"note\":\"Sequence, synonyms, formula and mass; CID 91810664.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-749","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\n
ARA-290\/Cibinetide: Small-Fiber Neuropathy and DME Trial Data<\/title>\n<meta name=\"description\" content=\"Human cibinetide evidence includes small exploratory studies with very different populations. A 22-person sarcoidosis-neuropathy pilot reported a symptom-s\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/essais-cliniques-sur-lara-290-le-cibinetide-la-neuropathie-des-petites-fibres-et-loedeme-diabetique-maculaire\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARA-290\/Cibinetide: Small-Fiber Neuropathy and DME Trial Data\" \/>\n<meta property=\"og:description\" content=\"Human cibinetide evidence includes small exploratory studies with very different populations. A 22-person sarcoidosis-neuropathy pilot reported a symptom-s\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/essais-cliniques-sur-lara-290-le-cibinetide-la-neuropathie-des-petites-fibres-et-loedeme-diabetique-maculaire\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cibinetide-small-fiber-evidence.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"ARA-290\\\/Cibinetide: Small-Fiber Neuropathy and DME Trial Data\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/\"},\"wordCount\":298,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cibinetide-small-fiber-evidence.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/\",\"name\":\"ARA-290\\\/Cibinetide: Small-Fiber Neuropathy and DME Trial Data\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cibinetide-small-fiber-evidence.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"Human cibinetide evidence includes small exploratory studies with very different populations. A 22-person sarcoidosis-neuropathy pilot reported a symptom-s\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cibinetide-small-fiber-evidence.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cibinetide-small-fiber-evidence.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Corneal and peripheral small-nerve-fiber research imaging for cibinetide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ARA-290\\\/Cibinetide: Small-Fiber Neuropathy and DME Trial Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ARA-290\/Cibinetide\u00a0: neuropathie des petites fibres et donn\u00e9es de l'essai DME","description":"Les preuves du cibin\u00e9tide humain comprennent de petites \u00e9tudes exploratoires aupr\u00e8s de populations tr\u00e8s diff\u00e9rentes. Un pilote de sarco\u00efdose-neuropathie sur une personne 22 a signal\u00e9 un sympt\u00f4me\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/essais-cliniques-sur-lara-290-le-cibinetide-la-neuropathie-des-petites-fibres-et-loedeme-diabetique-maculaire\/","og_locale":"fr_FR","og_type":"article","og_title":"ARA-290\/Cibinetide: Small-Fiber Neuropathy and DME Trial Data","og_description":"Human cibinetide evidence includes small exploratory studies with very different populations. A 22-person sarcoidosis-neuropathy pilot reported a symptom-s\u2026","og_url":"https:\/\/nhdbio.com\/fr\/essais-cliniques-sur-lara-290-le-cibinetide-la-neuropathie-des-petites-fibres-et-loedeme-diabetique-maculaire\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cibinetide-small-fiber-evidence.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"ARA-290\/Cibinetide: Small-Fiber Neuropathy and DME Trial Data","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/"},"wordCount":298,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cibinetide-small-fiber-evidence.webp","articleSection":["Published Study Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/","url":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/","name":"ARA-290\/Cibinetide\u00a0: neuropathie des petites fibres et donn\u00e9es de l'essai DME","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cibinetide-small-fiber-evidence.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"Les preuves du cibin\u00e9tide humain comprennent de petites \u00e9tudes exploratoires aupr\u00e8s de populations tr\u00e8s diff\u00e9rentes. Un pilote de sarco\u00efdose-neuropathie sur une personne 22 a signal\u00e9 un sympt\u00f4me\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cibinetide-small-fiber-evidence.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cibinetide-small-fiber-evidence.webp","width":1672,"height":941,"caption":"AI-generated illustration: Corneal and peripheral small-nerve-fiber research imaging for cibinetide"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/ara-290-cibinetide-small-fiber-neuropathy-and-dme-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"ARA-290\/Cibinetide: Small-Fiber Neuropathy and DME Trial Data"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=749"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/749\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/733"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Imagerie](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cibinetide-small-fiber-evidence.webp\")